Background: Systemic lupus erythematosus (SLE) patients are prone to develop idiopathic osteonecrosis (ION) compared to other connective tissue disease patients or healthy subjects. ION has been shown to occur as a result of ischemia, however, the involvement of antiphospholipid antibodies (aPL) in its pathophysiology remains to be elucidated. In the last years, our group introduced a quantitative marker of aPL "antiphospholipid score (aPL-S)", which well reflected the risk of developing thrombosis [1] . Objectives: We aimed to identify the impact of aPL on the development of ION using aPL-S. Methods: A single center retrospective study comprising 82 consecutive patients who were diagnosed SLE at the Rheumatology department of Hokkaido University Hospital and underwent magnetic resonance imaging (MRI) of hip joints from January 2000 to December 2016. Among all the enrolled patients, aPL-S, which is calculated from 0 to 86, as well as classical risk factors for ION were evaluated. (OR 16.11; 95% CI 4.01 to 92.54, p<0 .001) as independent variables. Of note, in 6 patients who had both high aPL-S and hypertriglyceridemia, 83% (5/6) developed ION ( Figure  1 ). Conversely, systemic lupus erythematosus disease activity index and pulsed methylprednisolone therapy were not identified as risk factors for ION.
Results

Conclusions:
We newly identified high aPL-S as a risk factor for ION. Furthermore, SLE patients who have both high aPL-S and hypertriglyceridemia are at very high risk of ION. These findings suggest the involvement of microvascular occlusion in the pathophysiology of ION in SLE. Table 2 . Cyclophosphamide treatment was given mostly for renal disease. Within 22 patients receiving rituximab, 2 had thrombocytopenia and 1 had hemolytic anemia unresponsive to other treatments, 1 had protein-losing enteropathy and 1 had lupus enteritis; the rest had lupus nephritis. One patient received intravenous immune globulin (IVIG) for severe neutropenia and 2 patients for severe thrombocytopenia. One patient received plasmapheresis for vasculitis. One patient received IVIG, plasmapheresis, rituximab for severe renal failure, alveolar hemorrhage requiring intensive care unit admission and 1 patient received same treatment for severe unresponsive hemolytic anemia. Steroid/pulse treatment (n, %) 294 (98%)/65 (21.6%) Hydroxycholoroquine (n, %) 300 (100%) Azathioprine (n, %) 196 (65.3%) Mycophenolate mofetil (n, %) 83 (27.6%) Cyclophosphamide (iv) (n, %) 78 (26%); 10±4.5 cycles (min-max: 2-17) Rituximab (n, %) 22 (7.3%) Intravenous immunglobulin (IVIG) (n, %) 7 (2.3%) Plasmapheresis (n, %) 4 (1.3%)
In long term, SLICC/ACR damage index was highest in patients received pulse steroid for renal disease (min:0, max:5). Four (1.3%) patients had pulmonary hypertension, 31 (10.3%) had avascular necrosis, 24 (8%) had viral infections requiring treatment or bacterial infections requiring admission due to immunosuppression, 12 (4%) had malignancy. SLE is an autoimmune disease requiring multi-faceted approach. Background: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown of blood brain barrier (BBB) plays a crucial role in the development of diffuse psychiatric/neuropsychological manifestations (diffuse NPSLE), allowing influx of neuron-reactive autoantibodies from systemic circulation into the brain. However, the mechanism of BBB damages remains unclear. On the other hand, although CSF interleukin-6 (IL-6) has been shown to be elevated in NPSLE, there has been no report on serum IL-6 in NPSLE. Objectives: The present study was designed in order to elucidate the roles of serum IL-6 in the pathogenesis, especially in development of BBB damages, In NPSLE. Methods: Paired serum and cerebrospinal fluid (CSF) samples were obtained from 101 SLE patients when they presented active neuropsychiatric manifestations (69 patients with diffuse psychiatric/neuropsychological syndromes [diffuse NPSLE] and 32 patients with neurologic syndromes or peripheral nervous system involvement [focal NPSLE]) and from 22 non-SLE control patients with non-
